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Surgical revision of complicated false and true
vascular access–related aneurysms
George S. Georgiadis, MD,a Miltos K. Lazarides, MD,a Stelios A. Panagoutsos, MD,b
Konstantia M. Kantartzi, MD,b Constantinos D. Lambidis, MD,c Dimitrios N. Staramos, MD,d and
Vassilios A. Vargemezis, MD,b Alexandroupolis and Athens, Greece
Purpose: This prospective observational study examined the effect of revision surgery in patients who present solely with
complicated arteriovenous access (AVA)-related aneurysms.
Methods: The demographics and comorbid conditions of 44 hemodialysis access patients who presented with complicated
true or false AVA-related aneurysms and underwent revision surgery during a 7-year period were prospectively entered
into our AVA database. Also recorded were AVA characteristics before and after revision. Arteriovenous access anatomy
was evaluated preoperatively using color Doppler ultrasonography, and AVA adequacy was assessed in all patients
postoperatively after the first needle puncture and every month thereafter. Postintervention access function and primary
patency rates were analyzed. Patency was evaluated using the Kaplan-Meier method and compared between groups of
patients with different AVA characteristics before and after revision using the log-rank test.
Results:The cases of initial AVAwith complicated aneurysms comprised 16 radiocephalic, 8 brachiocephalic, 2 basilic vein
transposition, and 18 prosthetic fistulas (7 and 11 of the lower and upper arm, respectively), of which 42 were
dysfunctional and 2 had thrombosed early at presentation. Primary indications for revision were danger of aneurysm
rupture in 26, duplication in graft aneurysm diameter in 18, painful aneurysm in 12, stenosis due to partial aneurysm
thrombosis in 12, shortness of the potential cannulation area in 12, aneurysm enlargement in 4, infected aneurysm in 2,
and completely thrombosed aneurysm in 2. The mean postintervention primary patencies were 93%, 82%, 57%, and 32%
at 3, 6, 12, and 24 months, respectively. The outcomes was better in autogenous than prosthetic corrections, in true than
false aneurysms, in patients with two or fewer than more than 2 previous AVAs on revised arms, and in forearm than
upper-arm corrections (P  .0197, P  .004, P  .0022, and P  .0225, respectively).
Conclusions: Surgical revision of complicated false and true AVA-related aneurysms reveals acceptable postintervention
primary patency rates and therefore is justified. This outcome measure was superior in the following specific groups of
corrections: autogenous were better than prosthetic, true aneurysms were better than false aneurysms, patients with one
or two previous AVAs in the revised arm were better than those with more than two previous accesses in the revised arm,
and finally, forearms were better than those in the upper arm. (J Vasc Surg 2008;47:1284-91.)There is growing evidence of the value of arteriovenous
access (AVA) rescue operations in hemodialysis patients.1,2
Of the several possible AVA-related complications that
need intervention, aneurysms are under-reported in the
literature.3 Aneurysms can complicate all types of AVA,4
and comprise false aneurysms secondary to trauma caused
by the repeated punctures as well as true aneurysms caused
by degeneration and subsequent dilatation of the wall of
native veins or biologic grafts.5
In false aneurysms, no vessel is present in the wall of the
dilatation nor is there any graft, whereas in true aneurysms,
the flow in an otherwise normal graft or autogenous fistula
continues to increase, and the vein or graft may continue to
enlarge. Aneurysm formation complicates 2% to 10% of
arteriovenous grafts,6-10 and a recent systematic review
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1284found that the incidence of aneurysm and false aneurysm
formation in both autogenous and polytetrafluoroethylene
(PTFE) upper extremity AVAs ranged between 0% and 6%
(median, 4%).11
Although small series have addressed the repair of
autogenous and graft-related false aneurysms, they have
exclusively used endovascular approaches.12-24 In this
study, we investigated the effect of revision operations on
the postintervention primary patency in 44 hemodialysis
patients who presented with complicated true or false an-
eurysms either as sole lesions or combined with other
access-related complications. The postintervention primary
patency was also compared between groups of patients and
between groups of patients with different AVA characteris-
tics before and after intervention.
METHODS
Study population. Between January 2000 and Janu-
ary 2007, all patients who presented at three vascular units
with a failing (dysfunctional) or failed (thrombosed) AVA
secondary to complicated true or false aneurysms were
prospectively assessed. Baseline data of patient demograph-
ics, cardiovascular risk factors underlying renal disease, and
comorbidities were obtained from the registry of each
dialysis unit. The study cohort consisted of 22 men and 22
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20-83 years). The clinical characteristics of this patient
population are listed in Table I.
Access characteristics. We identified 44 complicated
true or false AVA-related aneurysms that required salvage
operations, of which 31 arose as sole lesions, while the
remaining complicated ones were combined with stenosis
of type I (anastomotic venous area in autogenous fistulas or
arterial anastomotic area in prosthetic fistulas, N  6) type
II (needling vein segment or mid-graft area, N 9, or type
III (junctional in autogenous fistulas or venous anastomo-
sis in grafts, N  2) according to the recent proposal by
Mickley.25 A complicated AVA-related aneurysm was de-
fined as any aneurysm with one or more of the following
characteristics:
● Thinning or erosion of the overlying skin layer result-
ing in graft or fistula exposure, which is a sign of
impending rupture;
● compromised skin without signs of inflammation;
● erythema, purulent drainage, or draining sinus tract,
which are signs of local infection;
● pain overlying the aneurysm;
● duplication of the aneurysm diameter compared with
normal AVA diameter (only in grafts);
● rapidly expanding aneurysm;
● stenosis due to partial aneurysm thrombosis;
● aneurysm thrombosis; and
● shortness of the potential cannulation area.
Table I. Patient characteristics
Variable
No. (%), or mean  SD
(range)
Age, years 60.48  14.35 (20-83)
Male sex 22 (50)
Hypertension 23 (52.3)
Diabetes 11 (25)
Coronary artery disease 14 (31.2)
Congestive cardiac failure 3 (6.8)
Arrhythmia 4 (9.1)
Tobacco use 4 (9.1)
Hypercholesterolemia 16 (36.4)
Obesitya 8 (18.2)
Neoplasm 2 (4.5)
Recent renal transplantation 3 (6.8)
Underlying renal disease
Diabetes mellitus 9 (20.5)
Glomerulonephritis 11 (25)
Pyelonephritis (urolithiasis) 5 (11.4)
Pyelonephritis (other cause) 2 (4.5)
Polycystic kidneys 2 (4.5)
Immunoglobulin A nephropathy 1 (2)
Systemic lupus erythematosus 1 (2)
Hypertension 4 (9.1)
Rheumatoid arthritis 1 (2)
Renal vascular disease 1 (2)
Unknown 7 (15.9)
aObese patients with a body mass index of 30.0 to 39.9 kg/m2, or severely
or morbidly obese patients with a body mass index of 40.0 kg/m2 or
higher.Any patient with one or more of the above indications
was considered a candidate for entering the study. Patients
with stenotic lesions (type I, II, or III) in a preaneurysm or
postaneurysm fistula or in graft segments underwent steno-
sis revision, but only the latter when this was hemodynam-
ically significant (50%). Accurate AVA anatomic pathol-
ogy and aneurysm characteristics, including maximum
diameter, length, presence of intraluminal thrombus, ex-
traluminal turbulent blood flow, and percentage of possible
area stenosis in the aneurysm were measured or detected
preoperatively by color Doppler ultrasound (US) scans.
Proximal or distal stenotic lesions concomitant with an
enlarging aneurysm were also preoperatively detected by
US imaging.
The initial diagnosis of an aneurysm or false aneurysm
with its pulsating mass effect was usually made by physical
examination.6,26 Where present, puncture site bleeding
and compromised skin were easily detected by a clinical
examination. Other clinical criteria were also applied, in-
cluding poor thrill on palpation, high venous pressures, and
low blood-flow states on hemodialysis for failing accesses
when draining vein or graft stenosis was also a feature, and
thrill disappearance for failed accesses.
Revision surgery details. Salvage operation details
are presented in Table II. The best timing for surgical
correction of each failing access was considered to be 1 day
after a dialysis session. Similarly, for failed access, the access
thrombosis was treated as soon as possible, and always24
hours of onset, to minimize proximal extension of the
thrombus. Prophylactic intravenous antibiotics (vancomy-
cin, 1 g) were administered 2 hours before each procedure
independent of the type of correction performed.
Surgical correction of AVA was considered successful if
sufficient hemodialysis was possible through the remaining
usable vein or the old incorporated graft. We administered
local anesthesia in all revision surgery operations, which was
considered sufficient. When skin erosion, bleeding, or local
infection were the indications for the rescue operation,
bypass grafting around the lesion was performed with local
extra-anatomic bypass techniques, provided that the sec-
tions adjacent to the local infection were well incorporated
and that the remaining graft canal beyond the stumps was
free of fluid on a preoperative US scan. In cases with no
evidence of infection, an interposition Gore-Tex (W. L.
Gore & Associates, Flagstaff, Ariz) graft or a Baxter graft
(Baxter Healthcare Corp, Irvine, Calif) with diameter of 6
or 8 mm, or primary repair for small aneurysms in native
veins with kinking, preserved sufficient remaining vein or
old graft for ongoing dialysis.4,26
Anastomotic aneurysms or aneurysms close to the anas-
tomosis in native fistulas were managed with the creation of
a new anastomosis a few centimeters proximally in a fashion
similar to that for type I stenosis in the draining vein of a
native fistula.4 In combined cases with progression of an-
eurysm and concomitant stenosis of the draining vein sys-
tem or graft, both lesions were surgically corrected if the
degree of stenosis was 50% (hemodynamically signifi-
cant), in accordance with The National Kidney Foundation
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ommendations.27,28 Otherwise, only the aneurysm was
surgically corrected.
Concomitant aneurysms—even uncomplicated ones—
were corrected simultaneously if they were close to the
complicated ones and if the potential cannulation area
would be sufficient after revision. Additional care was taken
to secure hemostasis at the end of each procedure. The
intended first needle puncture of the revised PTFE portion
was performed30 days in each case. Access characteristics
and operation details are listed in Table II.
Fistula outcomes and follow-up. The functionality
and postintervention patency rates of corrected AVAs were
prospectively assessed. Fistula outcomes were defined at the
initiation of the study. Patency was defined as the ability to
successfully dialyze through the access and differed clini-
cally from a patent but nonfunctional access. A revised
autogenous or prosthetic fistula was deemed adequate for
dialysis if it was used for at least 1 month and achieved a
dialysis blood flow of 350 mL/min and 600 mL/min
Table II. Access characteristics and operation details
Access characteristics
Patients,
No. (%)
Type of access before revision
Radial-cephalic fistula (Brescia-Cimino) 16 (36.4)
Brachial-cephalic fistula 8 (18.2)
Basilic vein transposition 2 (4.5)
Forearm loop PTFE graft 5 (11.4)
Forearm straight PTFE graft 2 (4.5)
Upper arm loop PTFE graft 11 (26)
Previous access before revision
2 27 (61.4)
2 17 (38.6)
AVF status at revision
Failing 42 (95.5)
Failed 2 (4.5)
Aneurysms (complicated  uncomplicated), Total
No.
1 25 (56.8)
2 19 (43.2)
Remaining aneurysms (uncomplicated)
0 31 (70.5)
1 (tandem aneurysms) 13 (29.6)
Corrected aneurysms
True 16 (36.4)
False 28 (63.6)
Type of aneurysm revisionsa
Resection of the aneurysm(s) and
Interposition graft 24 (54.6)b
Stenotic segments and interposition graft 5 (11.4)
Segmental bypass around the lesion (rerouting
technique)
1 (2)
New radiocephalic anastomosisc 7 (15.9)
Primary repair 4 (9.1)
Bypass to more proximal vein 3 (6.8)
Partial resection and stenotic lesion angioplasty 1 (2)
AVF, Arteriovenous fistula; PTFE, polytetrafluoroethylene.
aOne patient received two types of revisions.
bOne vein graft
cIn autogenous radiocephalic fistulas.respectively, on at least six dialysis sessions.29,30A patent AVA functioning poorly, defined as access
with blood flow below threshold values due to hemody-
namically significant stenosis (50%), indicating impend-
ing failure, was the definition of a failing AVA. A patent
AVA with normal blood flow but not used successfully for
hemodialysis because of other problems, such as outflow
vein or in-graft aneurysms without stenosis but in danger
for rupture, infection, or steal, was also considered a failing
AVA (also nonfunctional AVAs).31
Revised access follow-up was considered censored if the
patient died, received a transplant with a patent access,
reached the end of the study period (Jan 31, 2007) with a
patent access, or when AVA information was no longer
available. Revised access failure was calculated from the
date of the first revision to the date of AVA definitive
clotting, second revision, abandonment of the access due to
inability to sustain adequate dialysis, new access, or change
in access type (peritoneal dialysis or permanent catheter).
Follow-up was completed in all patients, with a mean of
20.38 17.03 months (range, 2.0-70.5 months). Arterio-
venous access adequacy was assessed in all patients postop-
eratively, after the first puncture, and every month thereaf-
ter using color Doppler US imaging. Patients were
followed up with periodic clinical examinations and color
Doppler US scans or other complementary measures, in-
cluding dynamic pressure measurements, recirculation
studies, and fistulography, if necessary.
Statistical analysis. The main outcome measure was
the functional patency rate of the corrected access (postint-
ervention primary patency) and is presented here according
to recommended standards of reporting arteriovenous he-
modialysis accesses.31 Patency rates were assessed by life-
table analysis and presented as Kaplan-Meier curves.
Kaplan-Meier curves were developed for each AVA charac-
teristic and compared using log-rank tests.
Ten comparisons were performed between patient
groups and between patients with different initial or
postintervention AVA characteristics:
1. Number of previous AVAs on the revised arm: two or
less, more than two.
2. Autogenous vs prosthetic corrections.
3. Total number of aneurysms at presentation: two or
more vs one.
4. Maximum diameter of the corrected aneurysm: 4 vs
4 cm. We used the arbitrary threshold diameter of 4
cm because it is not possible to clearly separate small
and large AVA-related aneurysms.
5. Corrected false vs corrected true aneurysms.
6. Presence vs absence of lesions other than aneurysm.
7. Number of remaining uncomplicated aneurysms after
revision: none vs one or more.
8. Corrected aneurysms in men vs women.
9. Corrected aneurysms in patients aged 65 vs 65
years.
10. Corrections in the forearm vs upper arm.
Data were analyzed using SPSS 10.0 statistical software
(SPSS Inc, Chicago, Ill), with differences considered signifi-
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the standard deviation and 95% confidence intervals (CI).
RESULTS
The initial AVA with complicated aneurysms com-
prised 16 radiocephalic fistulas, 8 brachiocephalic fistulas, 2
basilic vein transposition fistulas, and 18 prosthetic fistulas
(7 and 11 of the lower and upper arm, respectively), of
which 42 were dysfunctional (failing) and 2 had throm-
bosed early (failed) at presentation. Another 17 patients
with AVA aneurysms needing intervention according to
KDOQI refused surgery. This group consisted of 9 radial–
cephalic, 3 brachial–cephalic fistulas, 3 prosthetic brachial–
axillary, and 2 prosthetic femoral–femoral accesses. Data
collected during the same study period revealed that 372
radial–cephalic fistulas, 203 brachial–cephalic fistulas, 44
basilic vein transpositions, 161 prosthetic lower arm ac-
cesses, 215 prosthetic upper arm accesses, and 48 pros-
thetic thigh accesses were performed (revision operations
excluded). Corresponding percentages of pseudoaneurysm
formation were 6.7%, 5.4%, 4.5%, 4.3%, 6.5%, and 4.2%,
respectively.
The median primary survival of the first AVA was
20.4  2.6 months (95% CI, 15.3-25.4 months). The
median primary survival of the first autogenous fistulas
before correction was 40  13.6 months (95% CI, 13.4-
66.6 months) and that of the first prosthetic fistulas before
correction was 12  4.7 months (95% CI, 2.7-21.3
months). As expected, aneurysms appeared much earlier in
prosthetic fistulas than in autogenous fistulas. The average
time necessary for the pseudoaneurysms to develop was
16.6 months in autogenous accesses and 13.9 months in
prosthetic accesses.
Primary indications leading to AVA revision were dan-
ger of aneurysm rupture in 26, of which 2 had thinning or
erosion of the skin layer overlying the aneurysm resulting in
graft or fistula exposure and 24 had compromised skin
without signs of inflammation or rapidly expanding aneu-
rysm, or both; duplication of the aneurysm diameter com-
pared with the normal graft diameter in 18; painful aneu-
rysm in 12; stenosis due to partial aneurysm thrombosis in
12, of which 5 had concomitant stenosis unrelated to
aneurysm; shortness of the potential cannulation area in 12;
aneurysm enlargement and concomitant stenosis in 4; in-
fected aneurysm in 2, and completely thrombosed aneu-
rysm in 2.
The mean size of complicated aneurysms was 3.64 cm
(range, 2-8 cm) Hemodynamically significant stenosis
(type I, II, or III) in preaneurysm or postaneurysm fistula
or graft segments was detected in 13 patients (17 lesions).
Twenty-six concomitant aneurysms were detected in 17
patients, of which four were also complicated.
Resection of the aneurysm and interposition grafting
was the most frequently performed revision surgery (24
cases), followed by resection of the aneurysm and new
proximal arteriovenous anastomosis (7 cases). A PTFE
graft of length of 2 to 8 cm and diameter of 6 mm (8 mm in
2 cases) was used in 23 patients. One patient received a veininterposition graft (saphenous vein). In 10 cases, the dis-
eased skin covering the aneurysm was resected and a new
wound suture line was created. No additional skin flap
procedure was required. Fistulography was performed in
eight cases to ensure a successful revision. The mean oper-
ative time was 65 minutes.
No significant complications occurred, with no deaths
at 1 month. Minor complications included two patients
with small hematomas and five with transient cutaneous
rashes. In all patients, a sufficient usable portion of AVA
remained for cannulation. All revised AVAs were punctured
either on the day of operation (with a delay of 4 to 6 hours)
or the next day. Inserted new PTFE grafts were cannulated
in all cases at 30 to 35 days after revision.
The postintervention primary patencies for all revised
AVAs were 93%  4%, 82%  6%, 71%  7%, 57%  7%,
41% 8%, and 32% 8% at 3, 6, 9, 12, 18, and 24 months,
respectively (Fig 1). The outcome in complicated AVA-
related aneurysms was better in autogenous than prosthetic
corrections (P  .0197; Fig 2; Appendix Table III, online
only), in true than false aneurysms (P  0.004; Fig 3;
Appendix Table V, online only), in patients with two or
fewer than more than 2 previous AVAs in the revised arm (P
 .0022, Fig 4; Appendix Table V online only version), and
in forearm than upper arm correction (P  .0225, Fig 5;
Appendix Table VI online only).
Primary patencies were 85%  7% at 6 months and
69%  9% at 12 months for revision of 26 aneurysms in
autogenous tissue and were significantly higher than rates
in 18 prosthetic grafts (78% 10% at 6 months, 39% 11%
at 12 months). The corrections were significantly better in
16 true aneurysms (94% 10% at 6 months, 75% 11% at
12 months) than in 28 false aneurysms (75%  8% at 6
months, 46%  9% at 12 months). Similarly, primary
patencies after correction of aneurysms were significantly
better in the 27 patients with two or fewer previous AVAs
than in the 17 with more than two in the revised arm
(85% 7% and 74% 8% vs 77% 10% and 29% 11% at
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Fig 1. Cumulative survival of all corrections in complicated arte-
riovenous access–related aneurysms.6 and 12 months, respectively).
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were superior in 23 forearm corrections compared with 21
upper arm corrections at 6 and 12 months (87%  7% and
70%10% vs 76% 9% and 42% 11%, respectively). The
total number of aneurysms at presentation (2 vs 1),
maximum diameter of the corrected aneurysm (4 vs 4
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Fig 2. Cumulative survival of autogenous vs prosthetic revisions
of arteriovenous access (AVA). SE, Standard error.
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Fig 3. Cumulative survival of revisions in true vs false aneu-
rysms.cm), remaining uncomplicated aneurysms after revision (0vs 1), other existing lesions except aneurysm (0 vs 1),
sex, and age (65 vs 65 years) did not affect postinter-
vention patency (P  .63, P  .38, P  .43, P  .96, P 
.83, and P  .27, respectively).
The median survival time in resected aneurysms was
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Fig 4. Cumulative survival of corrections in patients with two or
fewer previous arteriovenous access (AVA) vs more than two
previous AVAs on revised arm. SE, Standard error.
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Fig 5. Cumulative survival of lower arm vs upper arm corrections
in arteriovenous access (AVA)- related aneurysms. SE, Standard
error.13.0 2.7 months (95% CI, 7.7-18.3 months) when using
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1.7 months (95% CI, 14.2-20.8 months) after the creation
of a new proximal anastomosis. The postintervention pri-
mary patencies did not differ significantly between these
two techniques (P  .41).
Three patients died during the study period. One pa-
tient was switched to catheter therapy, 1 was switched to
peritoneal therapy, and 14 presented with new complica-
tions, including 2 with infection of PTFE segment, 10 with
AVA thrombosis, and 2 with a new false aneurysm at risk of
rupture. The surgeon who performed the access considered
that 10 of these 14 cases were unsalvageable; therefore, a
new access was created. The remaining four patients re-
ceived new corrections, consisting of interposition PTFE
grafting in three and PTFE grafting around the infected
area in one, respectively). The AVA was patent in all of the
remaining patients.
DISCUSSION
Aneurysms can complicate all types of AVAs4 and can be
managed either with conventional surgery or with endovascular
techniques (Appendix, online only).2,4,6,7,10,12-24,26-28,32-36 Al-
though long-term success can be achieved with an appro-
priate intervention, revision surgery is usually required.
Surgical correction of false aneurysms includes resection of
the involved segment and new graft interposition,4,7,9,37
aneurysm ligation followed by insertion of a bypass graft
adjacent to the old one,4,7,38 or primary repair (stump
reanastomosis).4,39 Other alternative treatment modalities
include duplex US-guided percutaneous thrombin injec-
tion into the false aneurysm21,40 or compression of the false
aneurysm (also under US guidance).41
Several endovascular reports published since 1992 have
described the intragraft percutaneous deployment of cov-
ered stents as an alternative treatment for excluding AVA-
related aneurysms while maintaining patency of a AVA
(Appendix Table VII online only.12-24 However, the mean
study sample size was only 5.8 patients (range, 1-18 pa-
tients), and the follow-ups were very limited. Surprisingly,
there is no report in the literature on the effect of revision
surgery in patients who present purely with complicated
true or false AVA-related aneurysms. Only Karabay et al42
have reported on purely surgical management of giant true
aneurysms complicating antebrachial arteriovenous fistulas,
but they did not mention the postintervention patency
rates.
Cavallaro et al39 also presented 26 aneurysms in autog-
enous forearm fistulas (among other rescue operations in
vascular access), of which 17 were treated by resection of
the aneurysm and primary repair and nine with proximal
reanastomosis. Similarly, among 144 secondary procedures
to maintain vascular access patency, Zibari et al,7 reported
20 false aneurysm corrections (3 in autogenous fistulas, 8 in
upper arm PTFE fistulas, and 9 in lower extremity PTFE
fistulas).7 However, there have been several reports of
surgical revisions for AVA-related aneurysms constituting
part of the reoperations for infection.43,44 Furthermore,
partial resection of an infected false aneurysm and segmen-tal bypass far from the “lesion” (the partial graft excision) is
usually mixed with other types of revisions, thus producing
conflicting results. The present study is the first in the
literature to our knowledge that has examined the outcome
of surgically revised AVA in patients who present with such
lesions (Appendix Figs 6A, B, and C, online only).
For autogenous fistulas, the postintervention primary
patencies obtained for all revised AVAs were 94%  4%,
82% 6%, 71% 7%, 57% 7%, 41% 8%, and 32% 8%
at 3, 6, 9, 12, 18, and 24 months, respectively. The postint-
ervention patency rates of this study concur with the results
of a recent review of 34 studies that addresses dialysis access
patency, with reported values for all autogenous and pros-
thetic fistulas of 72% and 58% at 6 months, respectively, and
51% and 33% at 18 months, respectively.11 Notably, in the
present study the patency rates were 85%  7% and 50% 
10% for autogenous revisions at 6 and 18 months, respec-
tively, and 78%  10% and 28%  11% for prosthetic
revisions, respectively. As shown, we had comparable re-
sults, but for revised accesses, competing best possible
available evidence from the literature.
Like previous extensive data on revised accesses,45 we
have shown that corrections of complicated AVA-related
aneurysms produce better results in the lower arm than in
the upper arm. The life-table analysis with log-rank testing
revealed that the postintervention primary patencies dif-
fered significantly at 6 and 18 months. The greater propor-
tion of autogenous fistulas in the lower than upper arm
position (70% vs 48%) could partly explain the better lower
arm patencies. As we have shown recently, short (6 cm)
interposition PTFE segments used for the revision of failing
or failed autologous AVFs do not alter the autologous
behavior of the initial access.2 Thus, those radiocephalic
fistulas (lower arm AVAs) with complicated true or false
aneurysms that underwent revision with interposition short
(6 cm) PTFE graft still behave like native arteriovenous
fistulas (almost all PTFE segments used in this study were
6 cm), the latter type having better performance of all
AVFs in the literature. Furthermore, in seven cases in the
lower arm, a new radiocephalic anastomosis was con-
structed. This surgical revision has the better patency out-
comes of all revision operations that have been reported in
the literature.2
Comparable differences were also seen in two other
specific groups of corrections. Predictably, postinterven-
tion primary patency was significantly greater in true revised
aneurysms and in patients with previous two or fewer AVAs
on a revised arm than the corresponding patencies in false
revised aneurysms and in patients with more than two
previous AVAs on the revised arm.
Comparison of the Kaplan-Meier curves showed that
the total number of aneurysms at presentation (2 vs 1),
maximum diameter of the corrected aneurysm (4 vs 4
cm), remaining uncomplicated aneurysms after revision (0
vs 1), other existing lesions except aneurysm (0 vs 1),
sex, and age (65 vs 65 years) have no impact on the
postintervention patency.
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(tandem aneurysms), it is the complicated aneurysm that
has the pivotal role regarding primary patency after any type
of rescue procedure. Furthermore, it seems that other
nonaneurysmal existing lesions do not contribute to lower
patency rates if successfully corrected. Size also does not
matter if a threshold aneurysm diameter of 4 cm is taken in
to account. Unlike other authors, who reported poorer
outcome in patients with large false aneurysms,46 we did
not observe any acute failures in aneurysms 4 cm. Endo-
vascular techniques (mechanical thrombectomy, throm-
bectomy plus aspiration, pharmacologic thrombolysis) in
large aneurysms may result in acute failures, possibly from
propagation of residual clot within the false aneurysm lead-
ing to eventual rethrombosis.46 We found no data in the
literature to date correlating the size of the aneurysm with
complications or long-term patency after exclusion or ex-
cision.
Finally, as expected, in long-standing autogenous or
prosthetic fistulas, age and sex are not the primary regula-
tors of patency. These results are differentiated from those
presented by Astor et al,47 in which men with grafts and
women with grafts and fistulas had a greater risk for a first
subsequent access procedure than did men with fistulas.
Also, improved benefit of autogenous fistulas vs PTFE
grafts has not been confirmed in older men (age 72
years).47
Increased intra-access pressure—usually attributed to
venous outflow obstruction—is the primary reason for an-
eurysm expansion.19,48 When these stenotic lesions are
hemodynamically significant, they must be corrected by
endovascular (PTA or thrombectomy/thrombolysis, or
both) or surgical (angioplasty, graft extension, or interpo-
sition grafting) methods in parallel with local aneurysm
repair.4,48 Vesely24 recently stated that graft-related false
aneurysm size can be stabilized by applying angioplasty to
proximal stenotic lesions, thus reducing the intragraft pres-
sure and blood flow into the aneurysm. Up to 73% of his
patients treated for prosthetic AVA-related false aneurysms
had hemodynamically significant stenosis that required an-
gioplasty.24 In our study, concomitant stenosis was present
in 13 cases (17 lesions), most of which were type I or II. We
encountered only four stenotic lesions at the time of sur-
gery far from the corrected access area. None had to be
treated after aneurysm repair (all stable lesions 50%).
CONCLUSION
This study has shown that surgical revision of compli-
cated false and true aneurysms in AVA produces acceptable
postintervention primary patency rates, indicating the effi-
cacy of this procedure. This outcome measure was superior
in the following specific groups of corrections: autogenous
better than prosthetic, true aneurysms better than false
aneurysms, patients with one or two previous AVAs in the
revised arm better than those patients with more than two
previous accesses, and finally, forearm AVAs better than
upper arm AVAs. Further surgical investigations are needed
to extrapolate these results, with direct comparisons madeusing endovascular studies to identify the optimal method,
as Gelbfish stated recently.49 (Appendix Table IV, online
only)
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Introducing arteriovenous access aneurysms. Review of the
endovascular repair of complicated AVA-related
aneurysms.
It is known that chronic renal failure patients tend to
stay on hemodialysis therapy for longer periods, and hence,
considerable effort must be devoted to creating autogenous
fistulas or at least repairing existing arteriovenous accesses
(AVAs).2 Those patients in whom native vein is not further
available are recognized to benefit from surgery to revise a
failing or failed AVA. This procedure can prolong the
lifespan of the access and preserve other future sites for
AVA creation.
The salvage procedures in complicated AVA-related
aneurysms performed during this study represent only a
small proportion of the many revision surgeries that have
been performed in our three vascular units. This is also the
case in the literature, where corrections of at least shunt
aneurysms constitute a small proportion (0.8% to 6.7%) of
all secondary interventions to maintain AVA patency.7,32,33
Among several AVA complications, failing or failed true or
false aneurysms represent an addition challenge for the
vascular access surgeon. Surprisingly, published data on this
are scarce and mainly refer to endovascular data (usually
from small series) dealing with complicated AVA-related
aneurysms.12-24
False and true aneurysms can complicate all types of
AVA.4 In false aneurysms, no vessel or graft is present in the
wall of the dilatation, whereas in true aneurysms, the flow in
an otherwise normal graft or autogenous fistula continues
to increase, and the vein or graft may continue to enlarge. It
has been reported that high systemic blood pressure, ve-
nous hypertension caused by compromised venous out-
flow, or even atherosclerosis can give rise to dilatation or
aneurysm formation over time. Dilatation over time and
true aneurysm formation is a possible scenario, especially in
veins, and most commonly in the cephalic vein of a Brescia-
Cimino fistula.
Autogenous fistulas develop more frequently true an-
eurysms, usually as a consequence of prestenotic vein out-
flow dilatation caused by increased pressure or as a conse-
quence of poststenotic dilatation resulting from increased
turbulence.4 With expanded polytetrafluoroethylene
(ePTFE) grafts, only false aneurysms are seen, most com-
monly originating from needle punctures.6,26 Rarely, graft
false aneurysms develop at the anastomotic site due to
dehiscence of the suture line.4 However, xenografts (eg,
bovine ureteric graft) used in complex hemodialysis access
surgery are frequently complicated with true aneurysm
formation and subsequent online thrombosis, leading to
access failure.34 Furthermore, the incidence of false aneu-
rysms and puncture site complications is reportedly higher
for nonreinforced PTFE grafts than for reinforced PTFE
grafts.26
It has been suggested that a careful needle puncture
technique, frequent rotation of puncture sites, and the use
of rigorous aseptic methods are fundamental to preservingthe long-term structural integrity of an AVA and decreasing
the incidence of false aneurysm formation.26,35 However, if
the AVA wall is damaged from repeated puncturing at the
same site, the increased intra-access pressure forces blood
into the surrounding tissue, especially in poorly incorpo-
rated grafts, thereby creating a peri-AVA hematoma and a
false aneurysm. Concomitant proximal stenotic lesions
contribute to and accelerate this process.4,24,36 On the
other hand, tissue ingrowth into a prosthetic fistula pro-
tects against false aneurysm development.21
Although fistula aneurysms or shunt aneurysms have no
negative impact on functionality in most patients and there-
fore do not need correction,17 untreated false aneurysms
are often associated with graft thrombosis, thromboembo-
lism, pain, skin erosion, infection, cosmetic problems, and
difficulty accessing the graft.20 Furthermore, they may
expand and rupture, resulting in significant blood loss. If
available puncture sites are limited or if the blood supply to
the skin overlying the aneurysm is compromised, predis-
posing patient to risk of bleeding, then surgical repair is
warranted.4,27
False aneurysms that exceed twice the initial graft di-
ameter or that rapidly expand should also be surgically
corrected, with stents only being used for false aneurysms
that are centrally located.28 Salvage of aneurysm-compli-
cated dialysis prosthetic grafts or autogenous fistulas, aimed
at restoring or maintaining patency, can be performed by
endovascular or surgical techniques. Interventions include
percutaneous deployment of stent grafts or surgical exci-
sion of the aneurysm and the placement of an interposition
graft.
Small false aneurysms with no signs of infection should
be followed up, but needle insertion into the area of the
false aneurysm should be avoided. According to recently
published guidelines, indications for surgical treatment of
false aneurysms include (1) rapid expansion, (2) size ex-
ceeding twice the diameter of the graft, (3) involvement of
the overlying skin, (4) signs of infection, and (5) shortness
of potential cannulation area.28
In contrast to false aneurysms, true native vein aneu-
rysms have a benign natural history and should be removed
only when they involve the arterial anastomosis; however,
needle insertion into the aneurysm should also be avoided.
It is obvious that any progressive enlargement of a true
aneurysm that eventually compromises the skin above the
fistula, or limits the potential cannulation zone, may also
require a revision procedure, as recognized in the latest
version of The National Kidney Foundation Kidney Dis-
ease Outcomes Quality Initiative.28
Several recent reports have shown promising results in
placing a stent graft to exclude a complicated AVA aneu-
rysm needing treatment (Appendix Table VII, online
only.12-24 However, the mean study sample size was only
5.8 patients (range, 1-18 patients, and the follow-up was
very limited. Only Vesely24 reported the results of postint-
ervention survival analyses using the Kaplan-Meier method.
Although the series have been small, and were case reports,
all of the reports include concern about the increased risk of
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 6 Georgiadis et al 1291.e2the covered stents used being crushed because they are
subjected to repeated cannulation several times a week.18,21
Nevertheless, self-expanding stents that are capable of re-
gaining their original shape once any applied external com-
pression is removed22 could theoretically reduce the risk of
structural deformity after dialysis needle insertion.21,23
Several authors have introduced a dialysis protocol that
does not involve puncturing the graft-bearing segment in
order to reduce aneurysm recurrence.17,22 For example,
the ultrathin Dacron mesh covering of the Cragg EndoPro
(Mintec, Freeport, Grand Bahamas) stent graft can be easily
damaged by a large dialysis needle. This stent can also be
severely deformed if the polypropylene sutures are cut
inadvertently during a dialysis session.17 Even stent graft
collapse and obliteration of the lumen is a possible scenario
when the punctured graft has to be compressed after re-
moval of dialysis needles.14 Furthermore, Sapoval et al13
observed in some patients an inflammatory reaction,
“postimplantation syndrome,” after placement of the
Cragg EndoPro stent.13
Recently Ryan et al20 advocated using a PTFE graft
containing a covered stent (Wallgraft, Boston Scientific,
Natick, Mass) soon after implantation. They reported that
covered stents (such as the Wallgraft type) with the cover-
ing on the outside, as well as stents with small interstices
between their struts, have a protective effect in repeated
dialysis cannulations, leading to a better seal. They attrib-
uted this to the smaller distance between the PTFE graft
and the polyethylene terephthalate covering of the Wall-
graft stent.20 Other authors have also endorsed a policy of
Appendix Table III (online only). Outcome of correcte
prosthetic AVAs
Interval (mo)
No. at
risk
No. failed during
interval
Autogenous correction
0-3 26 2
3-6 24 1
6-9 22 2
9-12 20 2
12-15 18 1
15-18 17 3
18-21 13 2
21-24 11 0
24-27 11 1
27-30 10 2
Prosthetic correction
0-3 18 1
3-6 17 3
6-9 14 3
9-12 11 3
12-15 7 0
15-18 6 1puncturing stented segments at the next dialysis ses-sions.13,23,24 Rhodes and Silas propose routine venipunc-
ture of covered stents at dialysis whilst allowing covered
stent portions to heal for at least 2 to 3 weeks.23
Others have changed earlier policies and now advocate
puncturing the stent graft portion 30 days after deploy-
ment.24 This policy appears more prudent, because the
protective fibrotic layer between the false aneurysm throm-
bus and the stent surface could act as a barrier to aneurysm
recurrence.24 In contrast, uncovered stents implanted for
false aneurysms definitely lose the opportunity for complete
occlusion in most cases.16
In addition to the structural differences between cov-
ered stents leading to different behavior after venipuncture,
the absence of a considerable decrease in aneurysm size
after the insertion of a covered stent may limit the cannu-
lation zone, especially for large aneurysms. Vesely24 re-
ported that two of 11 patients with Viabahn (W. L. Gore &
Associates, Flagstaff, Ariz) covered stents inserted in pros-
thetic fistulas still had large excluded false aneurysms that
interfered with needle cannulation. These patients eventu-
ally underwent surgical removal of the thrombi.24
Cosmetic problems due to remaining large throm-
bosed aneurysms should also be taken into account. Thus,
although the use of an endoprosthesis in AVA-related
aneurysms is a less invasive technique, it still has some
limitations. We agree with other authors that the safety of
covered stents in AVA for hemodialysis needs further inves-
tigation in prospective studies. However, improvements in
stent materials may lead to more durable and reliable en-
eriovenous access-related aneurysms in autogenous and
o. withdrawn
during
interval
Interval
patency
Cumulative
patency
Standard
error
0 0.923 0.923 0.052
1 0.917 0.847 0.07
0 0.909 0.769 0.082
0 0.9 0.692 0.09
0 0.944 0.654 0.093
1 0.765 0.5 0.098
0 0.846 0.423 0.097
0 1 0.423 0.097
0 0.91 0.385 0.095
0 0.8 0.308 0.09
0 0.944 0.944 0.054
0 0.824 0.778 0.098
0 0.786 0.611 0.115
1 0.636 0.389 0.115
1 0.857 0.333 0.111
0 0.833 0.278 0.105d art
Ndoprostheses.24
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June 20081291.e3 Georgiadis et alAppendix Table IV (online only). The outcome in complicated arteriovenous access-related aneurysms comparing
true and false aneurysms
0-3 16 0 0 1 1 0.06
3-6 16 1 0 0.938 0.938 0.097
6-9 15 2 0 0.867 0.813 0.099
9-12 13 1 0 0.923 0.75 0.115
12-15 12 1 0 0.917 0.688 0.124
False aneurysm
0-3 28 3 0 0.893 0.893 0.058
3-6 25 3 1 0.84 0.75 0.081
6-9 21 3 0 0.857 0.643 0.09
9-12 18 5 0 0.722 0.464 0.094
12-15 13 1 0 0.923 0.429 0.093Appendix Table V (online only). Outcome of corrected arteriovenous access-related aneurysms in patients with two
or fewer, or with than more than two previous AVAs in the revised arm
Interval (mo)
No. at
risk
No. failed during
interval
No. withdrawn
during
interval
Interval
patency
Cumulative
patency
Standard
error
2 previous AVA
0-3 27 2 0 0.926 0.926 0.05
3-6 25 1 1 0.92 0.852 0.068
6-9 23 2 0 0.913 0.778 0.08
9-12 21 1 0 0.952 0.741 0.084
12-15 20 1 0 0.95 0.704 0.087
15-18 19 3 1 0.79 0.556 0.095
2 previous AVA
0-3 17 1 0 0.941 0.941 0.057
3-6 16 2 1 0.813 0.765 0.998
6-9 13 3 0 0.769 0.588 0.119
9-12 10 4 1 0.5 0.294 0.11
12-15 5 0 1 0.8 0.235 0.102AVA, Arteriovenous access.Appendix Table VI (online only). Outcome of revised forearm compared with revised upper arm arteriovenous
access-related aneurysms
Interval (mon)
No. at
risk
No. failed during
interval
No. withdrawn
during interval
Interval
patency
Cumulative
patency
Standard
error
Forearm
0-3 23 2 0 0.913 0.913 0.058
3-6 21 1 0 0.952 0.867 0.07
6-9 20 3 0 0.85 0.739 0.091
9-12 17 1 0 0.941 0.696 0.095
12-15 16 0 0 1 0.696 0.095
15-18 16 3 1 0.75 0.522 0.104
Upper arm
0-3 21 1 0 0.952 0.952 0.046
3-6 20 3 1 0.8 0.762 0.092
6-9 16 2 0 0.875 0.667 0.098
9-12 14 4 1 0.643 0.423 0.108
12-15 9 1 1 0.778 0.333 0.102
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First author, year Type of angioaccess Treatment
Initial
success
(%)
Post-intervention
primary
patency (%)
Recurrencea3 mo 6 mo 12 mo
Selby,12 1992 Prosthetic fistula (7b) Detachable balloons 100 57 NS NS NS
Sapoval,13 1996 Prosthetic fistula (1) Cragg Endopro stent graft 100 100 100 100 NS
Criado,14 1997 Prosthetic fistula (1c, 1b) Palmaz covered stent 100 NS 50 NS NS
Ombrellaro,15 1997 Prosthetic forearm loop fistula (1) Homemade stent graft
(Palmaz  PTFE)
100 NS NS NS NS
Raynaud,16 1998 Prosthetic and autogenous fistulas (11) Uncovered Wallstent 82 82 82 NS 9
Hausegger,17 1998 Prosthetic fistula (3b) Crag Endo-Pro stent graft 100 NS 66 0 66
Rabindranauth,18 1998 Prosthetic fistula (2b) Homemade stent graft
(Palmaz  PTFE)
100 100 NS NS NS
Hein,19 2001 Thrombosed prosthetic fistula (16
loop,c 2 loopb)
Mechanical
thrombectomy
94 NS NS NS NS
Ryan,21 2002 Prosthetic fistula (2 loop forearm, 1
loop axilloaxillary), autogenous
fistula (1b)
Stent graft (Wallgraft) 100 100 75% NS 0
Najibi,20 2002 Prosthetic fistula (2,c 6b), autogenous
fistula (1c, 1b)
Stent graft (Wallgraft) 90 70 70 NS NS
Silas,22 2003 Prosthetic fistula (1,c 1b) Stent graft (Wallgraft) 100 100 100 100 NS
Rhodes,23 2005 Prosthetic fistula (3 loop forearm) Stent graft (Wallgraft) 100 100 33 33 33
Vesely,24 2005 Prosthetic loop fistula (8 antebrachial,
one upper arm, two thigh)
Viabahn endoprosthesis 100 71 20 0 18.2
NS, Not stated; PTFE, polytetrafluoroethylene
aUntil the end of follow-up.
bUpper arm location.
cForearm location.
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June 20081291.e5 Georgiadis et alFig 6 (online only). (A) Multiple pseudoaneurysms in a basilic
vein transposition fistula in the left upper arm of a 37-year-old
man. (B) Fistulography of the AVA. Notice the post-aneurysms
stenotic lesion. (C) Revision of the AVA. Surgical excision of all
aneurysms with the concomitant stenotic lesion. Placement of
PTFE 8mm interposition graft.
